Gillespie Robinson & Grimm Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,022 shares of the biopharmaceutical company’s stock after selling 1,826 shares during the quarter. Gillespie Robinson & Grimm Inc.’s holdings in Pfizer were worth $468,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Heritage Way Advisors LLC increased its stake in shares of Pfizer by 0.6% in the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the period. Natixis acquired a new position in shares of Pfizer during the second quarter valued at $258,466,000. Machina Capital S.A.S. increased its stake in Pfizer by 14.4% during the 2nd quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock valued at $1,899,000 after buying an additional 5,522 shares during the period. M Holdings Securities Inc. increased its stake in Pfizer by 27.9% during the 1st quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock valued at $1,692,000 after buying an additional 8,693 shares during the period. Finally, Integrated Wealth Concepts LLC increased its stake in Pfizer by 14.2% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after buying an additional 8,445 shares during the period. Institutional investors and hedge funds own 71.69% of the company’s stock.

Several equities analysts have commented on the stock. Goldman Sachs Group reissued a “buy” rating and set a $49.00 target price on shares of Pfizer in a research note on Monday, June 17th. Credit Suisse Group reiterated a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. JPMorgan Chase & Co. raised their price objective on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Finally, DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a research note on Wednesday, August 28th. Twelve research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $45.20.

In related news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Shares of PFE traded up $0.10 during mid-day trading on Thursday, hitting $35.79. The company’s stock had a trading volume of 352,365 shares, compared to its average volume of 20,235,098. The firm has a 50-day moving average price of $35.92 and a 200 day moving average price of $40.00. The stock has a market capitalization of $198.18 billion, a price-to-earnings ratio of 11.94, a PEG ratio of 2.85 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business’s revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.81 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 4.02%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a bull market?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.